Large, persistent delivery problem
Many retinal therapeutic approaches are limited by the ability to reach outer retinal or intracellular targets through practical administration routes.
Company
A platform company focused on retinal delivery and disease‑modifying ocular therapeutics.
Visiogene is developing proprietary delivery technologies and preclinical programs for serious ocular diseases, with a focus on practical ocular administration routes and therapeutic payloads matched to retinal disease biology.
Company highlights
Delivery technology paired with focused ocular programs.
Multiple shots on goal
AAV‑IKV and Nuc1 support wet AMD, glaucoma, dry AMD, retinal degeneration, and protein delivery programs while preserving platform expansion potential.
Founder-market fit
The company is led by an ocular gene therapy founder with prior company formation and program acquisition experience.
Contact Visiogene
For company information, collaborations, or strategic discussions, use the contact button below.
Optional future enhancement: replace this panel with a GoDaddy-compatible contact form or embedded form provider.
All product candidates are investigational. Information on this site does not constitute medical advice or product promotion.
Focus
Retinal delivery, disease biology, and platform optionality.
Visiogene is designed around the premise that delivery innovation can open ocular targets that remain difficult to reach with conventional vectors or biologic delivery strategies.
AAV‑IKV gene delivery
Designed for ocular gene transfer across retinal and anterior segment targets.
Nuc1 protein delivery
Designed to chaperone small and large molecules into retinal cells without chemical conjugation.
Focused therapeutic programs
Programs include wet AMD, glaucoma, undisclosed dry AMD complement biology, and undisclosed retinal degeneration biology.